Previous close | 28.74 |
Open | 30.91 |
Bid | 31.13 x 51100 |
Ask | 31.55 x 25600 |
Day's range | 30.54 - 31.58 |
52-week range | 21.14 - 36.37 |
Volume | |
Avg. volume | 2,231,311 |
Market cap | 46.333B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | 33.87 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.29 (0.92%) |
Ex-dividend date | 07 Feb 2024 |
1y target est | N/A |
ResMed stock jumped Friday after crushing sales estimates and wiping out worries that weight-loss drugs would squeeze sleep apnea device sales.
Integer Holdings' (ITGR) first-quarter results reflect robust Medical Sales, along with strength in all the product lines.
STOCKSTOWATCHTODAY BLOG Shares of ResMed were trading sharply higher after the medical devices company filed a quarterly report that left Wall Street cheering. On Friday, ResMed stock was rising 14% to $209.